Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „vilanterol“
Suchtreffer
Begriffe & Kennungen
Anoro Ellipta (previously Anoro) · 4.5 · Although no formal in vivo drug interaction studies have been performed, inhaled umeclidinium/vilanterol has b
Eintrag öffnenAnoro Ellipta (previously Anoro) · 4.5 · Beta2-adrenergic blockers may weaken or antagonise the effect of beta2-adrenergic agonists, such as vilanterol
Eintrag öffnenAnoro Ellipta (previously Anoro) · 4.5 · Both umeclidinium and vilanterol are substrates of the P-glycoprotein transporter (P-gp). The effect of the mo
Eintrag öffnenAnoro Ellipta (previously Anoro) · 4.5 · Clinically significant interactions mediated by umeclidinium/vilanterol at clinical doses are considered unlik
Eintrag öffnenAnoro Ellipta (previously Anoro) · 4.5 · Co-administration of umeclidinium/vilanterol with other long-acting muscarinic antagonists, long-acting beta2-
Eintrag öffnenAnoro Ellipta (previously Anoro) · 4.5 · Vilanterol is a substrate of cytochrome P450 3A4 (CYP3A4). Concomitant administration of strong CYP3A4 inhibit
Eintrag öffnenAnoro Ellipta (previously Anoro) · 4.8 · The safety profile of ANORO ELLIPTA is based on safety experience with umeclidinium/vilanterol and the individ
Eintrag öffnenElebrato Ellipta · 4.5 · Beta2-adrenergic blockers may weaken or antagonise the effect of beta2-adrenergic agonists, such as vilanterol
Eintrag öffnenElebrato Ellipta · 4.5 · Clinically significant drug interactions mediated by fluticasone furoate/umeclidinium/vilanterol at clinical d
Eintrag öffnenElebrato Ellipta · 4.5 · Fluticasone furoate and vilanterol are rapidly cleared by extensive first pass metabolism mediated by enzyme C
Eintrag öffnenElebrato Ellipta · 4.5 · Fluticasone furoate, umeclidinium and vilanterol are substrates of the P-glycoprotein transporter (P-gp). The
Eintrag öffnenElebrato Ellipta · 4.8 · 8 comparable with that observed in the fluticasone furoate/vilanterol (FF/VI) 100/25 arm of FF/VI clinical stu
Eintrag öffnenRelvar Ellipta · 4.5 · 8 respectively. The increase in vilanterol exposure was not associated with an increase in beta2-agonist relat
Eintrag öffnenRelvar Ellipta · 4.5 · Clinically significant drug interactions mediated by fluticasone furoate/vilanterol at clinical doses are cons
Eintrag öffnenRelvar Ellipta · 4.5 · Clinically significant drug interactions mediated by fluticasone furoate/vilanterol at clinical doses are cons
Eintrag öffnenRelvar Ellipta · 4.5 · Fluticasone furoate and vilanterol are both rapidly cleared by extensive first pass metabolism mediated by the
Eintrag öffnenRelvar Ellipta · 4.5 · Fluticasone furoate and vilanterol are both rapidly cleared by extensive first pass metabolism mediated by the
Eintrag öffnenRelvar Ellipta · 4.5 · Fluticasone furoate and vilanterol are both substrates of P-glycoprotein (P-gp). A clinical pharmacology study
Eintrag öffnenRelvar Ellipta · 4.5 · Fluticasone furoate and vilanterol are both substrates of P-glycoprotein (P-gp). A clinical pharmacology study
Eintrag öffnenRelvar Ellipta · 4.8 · The most commonly reported adverse reactions with fluticasone furoate and vilanterol were headache and nasopha
Eintrag öffnen